What is OKYO Pharma's operating income?

OKYO Pharma's total operating income in 2025 was -$7.09 million, based on the following breakdown: Total Gross Profit: $0.00 Total Operating Expenses: $7.09 million

OKYO Pharma (OKYO) Financials

$1.42 +0.04 (+2.90%)

As of 03:51 PM Eastern

Compare

Annual Income Statements for OKYO Pharma

This table shows OKYO Pharma's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Net Income / (Loss) Attributable to Common Shareholders	-1.54	-3.35	-5.43	-13	-17	-4.71
Consolidated Net Income / (Loss)	-1.54	-3.35	-5.43	-13	-17	-4.71
Net Income / (Loss) Continuing Operations	-1.54	-3.35	-5.43	-13	-17	-4.71
Total Pre-Tax Income	-1.62	-3.38	-6.22	-13	-17	-7.97
Total Operating Income	-1.62	-3.38	-6.22	-13	-16	-7.09
Total Gross Profit	-0.97	0.00	-4.61	-6.85	-7.51	0.00
Total Revenue	0.05	0.00	0.00	0.00	0.00	0.00
Total Cost of Revenue	1.02	0.00	4.61	6.85	7.51	0.00
Total Operating Expenses	0.65	3.38	1.61	6.34	8.10	7.09
Research & Development Expense	0.52	0.35	1.61	6.34	8.24	2.25
Other Operating Expenses / (Income)	-	3.02	-	-	-0.14	4.84
Total Other Income / (Expense), net	0.00	-0.00	0.00	-0.10	-1.05	-0.88
Interest Expense	-	0.00	-	-	-	0.88
Income Tax Expense	-0.08	-0.02	-0.79	-0.01	0.02	-3.26
Basic Earnings per Share	$0.00	($0.32)	($0.36)	($0.61)	($0.57)	($0.20)
Diluted Earnings per Share	$0.00	($0.32)	($0.36)	($0.61)	($0.57)	($0.20)

No quarterly income statements for OKYO Pharma are available.

This table details how cash moves in and out of OKYO Pharma's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2020	2021	2022	2023	2024	2025
Period end date	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Net Change in Cash & Equivalents	-0.37	6.21	-3.32	7.55	6.22	3.70
Net Cash From Operating Activities	-1.20	-1.60	-5.47	0.23	0.01	2.00
Net Cash From Continuing Operating Activities	-1.42	-1.72	-5.59	0.23	0.01	2.00
Net Income / (Loss) Continuing Operations	-1.62	-3.38	-6.22	0.00	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	0.05	0.55	1.73	0.23	0.01	2.00
Net Cash From Investing Activities	-0.13	-0.02	-0.00	0.00	0.00	0.00
Net Cash From Continuing Investing Activities	-0.13	-0.02	-0.00	0.00	0.00	0.00
Net Cash From Financing Activities	0.96	7.83	2.15	7.32	6.21	1.71
Net Cash From Continuing Financing Activities	1.48	7.81	0.00	7.32	6.21	1.71
Issuance of Debt	0.50	7.59	0.00	7.32	6.21	1.71

No quarterly cash flow statements for OKYO Pharma are available.

This table presents OKYO Pharma's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2021	2022	2023	2024	2025
Period end date	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
Total Assets	7.09	4.30	5.20	1.54	3.68
Total Current Assets	6.99	4.30	5.20	1.54	3.68
Cash & Equivalents	6.89	2.70	4.05	0.83	1.56
Accounts Receivable	0.04	1.59	0.56	0.56	1.87
Plant, Property, & Equipment, net	0.01	0.01	0.01	0.00	0.00
Plant, Property & Equipment, gross	-	0.01	0.01	0.00	0.00
Total Noncurrent Assets	0.10	0.01	0.00	0.00	0.00
Total Liabilities & Shareholders' Equity	7.09	4.30	5.20	1.54	3.68
Total Liabilities	1.77	1.35	7.26	7.42	9.23
Total Current Liabilities	1.71	1.35	7.26	7.42	9.23
Accounts Payable	1.67	1.35	5.04	7.42	9.23
Total Noncurrent Liabilities	0.06	1.35	2.22	0.00	0.00
Total Equity & Noncontrolling Interests	7.12	5.89	-2.05	-5.88	-6.50
Total Preferred & Common Equity	5.32	2.95	-2.05	-5.88	-6.50
Total Common Equity	-105	2.95	-2.05	-5.88	-5.55
Retained Earnings	-106	-112	-126	-143	-143
Other Equity Adjustments	1.50	115	124	137	137

No quarterly balance sheets for OKYO Pharma are available.

This table displays calculated financial ratios and metrics derived from OKYO Pharma's official financial filings.

Metric	2020	2021	2022	2023	2024	2025
Period end date	3/31/2020	3/31/2021	3/31/2022	3/31/2023	3/31/2024	3/31/2025
DEI Shares Outstanding	0.00	0.00	0.00	1,374,415,468.00	25,553,274.00	33,836,316.00
DEI Adjusted Shares Outstanding	0.00	0.00	0.00	1,374,415,468.00	25,553,274.00	33,836,316.00
DEI Earnings Per Adjusted Shares Outstanding	0.00	0.00	0.00	-0.01	-0.66	-0.14
Growth Metrics	-	-	-	-	-	-
Revenue Growth	0.00%	-100.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Growth	0.00%	-108.40%	-84.74%	-113.73%	-25.43%	57.44%
EBIT Growth	0.00%	-108.44%	-84.09%	-113.65%	-25.43%	57.44%
NOPAT Growth	0.00%	-108.44%	-84.09%	-112.10%	-18.36%	54.56%
Net Income Growth	0.00%	-117.19%	-61.95%	-144.37%	-26.78%	72.03%
EPS Growth	0.00%	0.00%	-12.50%	-69.44%	6.56%	64.91%
Operating Cash Flow Growth	0.00%	-33.12%	-241.71%	104.17%	-95.01%	17,472.67%
Free Cash Flow Firm Growth	0.00%	0.00%	-497.65%	-21.75%	-45.88%	47.68%
Invested Capital Growth	0.00%	0.00%	29.37%	-306.41%	-53.24%	-7.21%
Revenue Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
NOPAT Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Income Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
EPS Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Cash Flow Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Invested Capital Q/Q Growth	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Profitability Metrics	-	-	-	-	-	-
Gross Margin	-2,064.39%	0.00%	0.00%	0.00%	0.00%	0.00%
EBITDA Margin	-3,437.24%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Margin	-3,449.97%	0.00%	0.00%	0.00%	0.00%	0.00%
EBIT Margin	-3,449.97%	0.00%	0.00%	0.00%	0.00%	0.00%
Profit (Net Income) Margin	-3,287.54%	0.00%	0.00%	0.00%	0.00%	0.00%
Tax Burden Percent	95.29%	99.26%	87.35%	99.91%	100.13%	59.05%
Interest Burden Percent	100.00%	100.03%	100.00%	100.00%	100.85%	112.38%
Effective Tax Rate	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Equity (ROE)	0.00%	-47.08%	-83.44%	-690.95%	424.20%	76.04%
Cash Return on Invested Capital (CROIC)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Return on Assets (OROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Assets (ROA)	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Return on Common Equity (ROCE)	0.00%	690.75%	650.97%	-160.83%	424.20%	70.20%
Return on Equity Simple (ROE_SIMPLE)	0.00%	-63.04%	-184.27%	646.38%	286.17%	72.41%
Net Operating Profit after Tax (NOPAT)	-1.13	-2.36	-4.35	-9.23	-11	-4.96
NOPAT Margin	-2,414.98%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Nonoperating Expense Percent (NNEP)	0.00%	-22.79%	-13.76%	-85.80%	-346.90%	28.17%
Return On Investment Capital (ROIC_SIMPLE)	-	-	-	-5,702.61%	185.83%	76.38%
Cost of Revenue to Revenue	2,164.39%	0.00%	0.00%	0.00%	0.00%	0.00%
SG&A Expenses to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
R&D to Revenue	1,103.11%	0.00%	0.00%	0.00%	0.00%	0.00%
Operating Expenses to Revenue	1,385.58%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings before Interest and Taxes (EBIT)	-1.62	-3.38	-6.22	-13	-17	-7.09
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	-1.61	-3.36	-6.22	-13	-17	-7.09
Valuation Ratios	-	-	-	-	-	-
Price to Book Value (P/BV)	0.00	0.00	0.85	0.00	0.00	0.00
Price to Tangible Book Value (P/TBV)	0.00	0.00	0.85	0.00	0.00	0.00
Price to Revenue (P/Rev)	53.23	0.00	0.00	0.00	0.00	0.00
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Revenue (EV/Rev)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBITDA (EV/EBITDA)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	0.00	0.00	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	0.00	0.00	0.00	0.00	3,275.37	20.72
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-
Debt to Equity	0.00	0.01	0.00	-1.08	0.00	0.00
Long-Term Debt to Equity	0.00	0.01	0.00	-1.08	0.00	0.00
Financial Leverage	0.00	-1.22	-1.20	-2.45	0.43	0.15
Leverage Ratio	0.00	1.00	0.88	2.47	-0.85	-0.42
Compound Leverage Factor	0.00	1.00	0.88	2.47	-0.86	-0.47
Debt to Total Capital	0.00%	0.90%	0.00%	1,368.42%	0.00%	0.00%
Short-Term Debt to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	0.00%	0.90%	0.00%	1,368.42%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	1,553.09%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	50.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	0.00%	-1,453.99%	50.00%	-1,268.42%	100.00%	85.38%
Debt to EBITDA	0.00	-0.02	0.00	-0.17	0.00	0.00
Net Debt to EBITDA	0.00	2.03	0.00	0.14	0.00	0.00
Long-Term Debt to EBITDA	0.00	-0.02	0.00	-0.17	0.00	0.00
Debt to NOPAT	0.00	-0.03	0.00	-0.24	0.00	0.00
Net Debt to NOPAT	0.00	2.89	0.00	0.20	0.00	0.00
Long-Term Debt to NOPAT	0.00	-0.03	0.00	-0.24	0.00	0.00
Altman Z-Score	0.00	-20.76	-39.44	0.00	-166.64	-59.83
Noncontrolling Interest Sharing Ratio	0.00%	1,567.18%	880.16%	76.72%	0.00%	7.67%
Liquidity Ratios	-	-	-	-	-	-
Current Ratio	0.00	4.09	3.17	0.72	0.21	0.40
Quick Ratio	0.00	4.06	3.17	0.63	0.19	0.37
Cash Flow Metrics	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	0.00	-0.80	-4.81	-5.86	-8.54	-4.47
Operating Cash Flow to CapEx	0.00%	-23,047.65%	-327,625.22%	0.00%	0.00%	0.00%
Free Cash Flow to Firm to Interest Expense	0.00	-716.71	0.00	0.00	0.00	-5.09
Operating Cash Flow to Interest Expense	0.00	-1,424.93	0.00	0.00	0.00	2.28
Operating Cash Flow Less CapEx to Interest Expense	0.00	-1,431.11	0.00	0.00	0.00	2.28
Efficiency Ratios	-	-	-	-	-	-
Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Receivable Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Inventory Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Fixed Asset Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Accounts Payable Turnover	0.00	0.00	3.05	2.14	1.20	0.00
Days Sales Outstanding (DSO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Inventory Outstanding (DIO)	0.00	0.00	0.00	0.00	0.00	0.00
Days Payable Outstanding (DPO)	0.00	0.00	119.86	170.40	303.01	0.00
Cash Conversion Cycle (CCC)	0.00	0.00	0.00	0.00	0.00	0.00
Capital & Investment Metrics	-	-	-	-	-	-
Invested Capital	0.00	-1.56	-1.10	-4.48	-6.86	-7.35
Invested Capital Turnover	0.00	0.00	0.00	0.00	0.00	0.00
Increase / (Decrease) in Invested Capital	0.00	-1.56	0.46	-3.37	-2.38	-0.49
Enterprise Value (EV)	0.00	107	2.75	0.00	37	41
Market Capitalization	2.50	2.50	2.50	0.00	38	43
Book Value per Share	$0.00	($167.21)	$4.72	$0.00	($9.41)	($0.16)
Tangible Book Value per Share	$0.00	($167.21)	$4.72	$0.00	($9.41)	($0.16)
Total Capital	0.00	7.19	5.89	0.16	-5.88	-6.50
Total Debt	0.00	0.06	0.00	2.22	0.00	0.00
Total Long-Term Debt	0.00	0.06	0.00	2.22	0.00	0.00
Net Debt	0.00	-6.82	-2.70	-1.83	-0.83	-1.56
Capital Expenditures (CapEx)	0.00	0.01	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)	0.00	-1.61	0.24	-6.11	-6.71	-7.11
Debt-free Net Working Capital (DFNWC)	0.00	5.28	2.94	-2.06	-5.88	-5.55
Net Working Capital (NWC)	0.00	5.28	2.94	-2.06	-5.88	-5.55
Net Nonoperating Expense (NNE)	0.41	0.99	1.08	4.04	5.90	-0.26
Net Nonoperating Obligations (NNO)	0.00	-8.68	-7.00	-2.42	-0.98	-0.85
Total Depreciation and Amortization (D&A)	0.01	0.01	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt-free Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Net Working Capital to Revenue	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Adjustments	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.00	$0.00	($0.01)	($0.61)	($0.57)	($0.20)
Adjusted Weighted Average Basic Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Diluted Earnings per Share	$0.00	$0.00	($0.01)	($0.61)	($0.57)	($0.20)
Adjusted Weighted Average Diluted Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	($0.01)	$0.00	($0.57)	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	0.00	0.00	0.00	0.00	0.00	0.00
Normalized Net Operating Profit after Tax (NOPAT)	-1.04	-2.36	-4.35	-9.23	-11	-4.96
Normalized NOPAT Margin	-2,217.25%	0.00%	0.00%	0.00%	0.00%	0.00%
Pre Tax Income Margin	-3,449.97%	0.00%	0.00%	0.00%	0.00%	0.00%
Debt Service Ratios	-	-	-	-	-	-
EBIT to Interest Expense	0.00	-3,007.46	0.00	0.00	0.00	-8.08
NOPAT to Interest Expense	0.00	-2,105.22	0.00	0.00	0.00	-5.65
EBIT Less CapEx to Interest Expense	0.00	-3,013.64	0.00	0.00	0.00	-8.08
NOPAT Less CapEx to Interest Expense	0.00	-2,111.40	0.00	0.00	0.00	-5.65
Payout Ratios	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

No quarterly metrics and ratios for OKYO Pharma are available.

Financials Breakdown Chart

OKYO Pharma Financials - Frequently Asked Questions

According to the most recent income statement we have on file, OKYO Pharma's fiscal year ends in March. Their fiscal year 2025 ended on March 31, 2025.

OKYO Pharma's net income appears to be on an upward trend, with a most recent value of -$4.71 million in 2025, rising from -$1.54 million in 2020. The previous period was -$16.83 million in 2024. Check out OKYO Pharma's forecast to explore projected trends and price targets.

OKYO Pharma's total operating income in 2025 was -$7.09 million, based on the following breakdown:

Total Gross Profit: $0.00
Total Operating Expenses: $7.09 million

Over the last 5 years, OKYO Pharma's total revenue changed from $46.97 thousand in 2020 to $0.00 in 2025, a change of -100.0%.

OKYO Pharma's total liabilities were at $9.23 million at the end of 2025, a 24.3% increase from 2024, and a 420.7% increase since 2021.

In the past 4 years, OKYO Pharma's cash and equivalents has ranged from $826.85 thousand in 2024 to $6.89 million in 2021, and is currently $1.56 million as of their latest financial filing in 2025.

Over the last 5 years, OKYO Pharma's book value per share changed from 0.00 in 2020 to -0.16 in 2025, a change of -16.4%.

Related Companies

Financial statements for NASDAQ:OKYO last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

OKYO Pharma (OKYO) Financials

Financials Breakdown Chart

OKYO Pharma Financials - Frequently Asked Questions

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

OKYO Pharma (OKYO) Financials

Annual Income Statements for OKYO Pharma

Quarterly Income Statements for OKYO Pharma

Annual Cash Flow Statements for OKYO Pharma

Quarterly Cash Flow Statements for OKYO Pharma

Annual Balance Sheets for OKYO Pharma

Quarterly Balance Sheets for OKYO Pharma

Annual Metrics And Ratios for OKYO Pharma

Quarterly Metrics And Ratios for OKYO Pharma

Financials Breakdown Chart

OKYO Pharma Financials - Frequently Asked Questions

When does OKYO Pharma's financial year end?

How has OKYO Pharma's net income changed over the last 5 years?

What is OKYO Pharma's operating income?

How has OKYO Pharma's revenue changed over the last 5 years?

How much debt does OKYO Pharma have?

How much cash does OKYO Pharma have?

How has OKYO Pharma's book value per share changed over the last 5 years?

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools